Research programme: anti-inflammatory kinase inhibitors - Arrien Pharmaceuticals

Drug Profile

Research programme: anti-inflammatory kinase inhibitors - Arrien Pharmaceuticals

Alternative Names: ARN-4026; ARN-4079; ATP-competitive kinase inhibitors - Arrien Pharmaceuticals; JAK3 inhibitors - Arrien Pharmaceuticals; JAK3/ITK inhibitors - Arrien Pharmaceuticals

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arrien Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis; Rheumatoid arthritis
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing for Rheumatoid arthritis (Arrien Pharmaceuticals Pipeline, September 2016)
  • 26 Nov 2015 No development reported for Chronic obstructive pulmonary disease in USA (PO)
  • 26 Nov 2015 Preclinical trials in Psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top